# Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects

> **NCT06063291** · PHASE1 · COMPLETED · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 36 (actual)

## Conditions studied

- Healthy Adult Subjects

## Interventions

- **DRUG:** ID110521156
- **DRUG:** Placebo of ID110521156

## Key facts

- **NCT ID:** NCT06063291
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-20
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-07-11
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2024-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06063291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06063291, "Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06063291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*